CONMED Q3 sales rise 6.7% to $337.9 million; GAAP EPS falls to $0.09
CONMED reported third quarter 2025 sales of $337.9 million, up 6.7% year over year, while GAAP diluted EPS fell to $0.09 from $1.57 a year earlier, after product rationalization costs and other charges. The company also raised the midpoint of its adjusted EPS guidance, authorized a $150.0 million share repurchase program, and suspended its quarterly cash dividend, which matters to shareholders because it changes how cash is returned to them.
Key points
- Q3 2025 sales were $337.9 million, up 6.7% as reported and 6.3% in constant currency.
- GAAP diluted EPS was $0.09 versus $1.57 in Q3 2024; adjusted diluted EPS was $1.08 versus $1.05.
- Full-year 2025 adjusted diluted EPS guidance is $4.48 to $4.53, compared with the prior $4.40 to $4.55.
- Board authorized a $150.0 million buyback effective October 31, 2025 and suspended the quarterly dividend; at least $25.0 million in annual repurchases is expected from 2026.
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.